DOI: https://doi.org/10.22141/2224-0551.7.50.2013.84895

Antibiotic-associated diarrhea: mechanisms of development and possible correction

L.V. Zakordonets, S.A. Kramarev, T.V. Beregova, A.N. Tolstanova, T.V. Dovbynchuk

Abstract


The article presents the current views on the mechanisms of diarrhea associated with antibiotics, describes methods of treatment and prevention of antibiotic-associated diarrhea. The experimental results proved the feasibility of ­using Saccharomyces boulardii (Enterol) for the prevention of diarrhea caused by the use of broad-spectrum antibiotics.


Keywords


antibiotic-associated diarrhea; diarrhea; antibio­tics; Saccharomyces boulardii; Clostridium difficile; ceftriaxone

References


Wistrom J., Norrby S.R., Myhre E.B. Frequency of antibiotic-associated diarrhoea in 2462 antibiotic-treated hospitalized patients: a prospective study // J. Antimicrob. Chemother. — 2001. — Vol. 47. — P. 43-50.

Bartlett J.G. Antibiotic-associated diarrhea // N. Engl. J. Med. — 2002. — Vol. 346, № 5. — Р. 334-339.

LaRosa M., Bottaro G., Gulino N. Prevention of antibiotic-associated diarrhea with Lactobacillus sporogens and fructo-oligosaccharides in children: a multicentric double-blind vs. placebo study // Minerva Pediatr. — 2003. — № 55. — Р. 447-452.

Turck D., Bernet J.P., Marx J. et al. Incidence and risk factors of oral antibiotic-associated diarrhea in an outpatient pediatric population // J. Pediatr. Gastroenterol. Nutr. — 2003. — № 37. — Р. 22-26.

Майданник В.Г. Антибиотикассоциированная диарея, связанная с Clostridium difficile // Здоров’я України. — 2010. — С. 20-22.

McFarland L.V., 2010 Probiotics and Diarrhea // Ann. Nutr. Metab. — 2010. — № 57 (suppl. 1). — Р. 10-11.

Vonberg R.P., Reichardt C., Behnke M. et al. Cost of nosocomial Clostridium difficile-associated diarrhea // J. Hosp. Infect. — 2008. — Vol. 70. — Р. 15-20.

McFarland L.V. Epidemiology, risk factors and treatments for antibiotic-associated diarrhea // Dig. Dis. — 1998. — Vol. 16. — P. 292-307.

Lusk R.H., Fekety F.R., Silva J.J., Bodendorfer T., Devine B.J., Kawanishi H., Korff L., Nakauchi D., Rogers S., Siskin S.B. Gastrointestinal side effects of clindamycin and ampicillin therapy // J. Infect. Dis. — 1977. — Suppl. 135. — P. 111-119.

Clausen M.R., Bonnen H., Tvede M., Brobech-Mortensen P. Colonic fermentation to short-chain fatty acids is decreased in antibiotic-associated diarrhea // Gastroenterology. — 1991. — Vol. 101. — Р. 1497-504.

Hogenauer C., Hammer H.F., Krejs G.J., Reisinge, E.C. Mechanisms and management of antibiotic-associated diarrhea // Clin. Infect. Dis. — 1998. — Vol. 27. — P. 702-710.

DobbinsW.O., Herrero B.A., Mansbach C.M. Morphologic alterations associated with neomycin induced malabsorption // Am. J. Med. Sci. — 1968. — Suppl. 225. — P. 63-77.

Ивашкин В.Т., Трухманов А.С. Болезни пищевода. Патологическая физиология, клиника, диагностика, лечение. — М., 2000. — 184 с.

David M.S., Donald H.A., Fabio B. Association Between Antibiotic Use and Primary Idiopathic Intussusception // Arch. Pediatr. Adolesc. Med. — 2003. — Suppl. 157(1). — P. 54-59.

Cartman S.T., Heap J.T., Kuehne S.A., Cockayne A., Minton N.P., 2010. The emergence of ‘hypervirulence’ in Clostridium difficile // International Journal of Medical Microbiology. — 2010. — Vol. 300. — P. 387-395.

National Clostridium difficile Standards Group. Report to the Department of Health // J. Hosp. Infect. — 2004. — Vol. 56 (suppl. 1). — P. 1-38.

Hell M., Bernhofer C., Stalzer P., Kern J.M., Claassen E. Probiotics in Clostridium difficile infection: reviewing the need for a multistrain probiotic // Beneficial Microbes. — 2013. — № 4(1). — P. 39-51.

Bauer M.P., Kuijper E.J., van Dissel J.T. European Society of Clinical Microbiology and Infectious Diseases. European Society of Clinical Microbiology and Infectious Diseases (ESCMID): treatment guidance document for Clostridium difficile infection (CDI) // Clin. Microbiol. Infect. — 2009. — № 15(12). — P. 1067-1079.

Musher D.M., Aslam S., Logan N. et al. Relatively poor outcome after treatment of Clostridium difficile colitis with metronidazole // Clin. Infect. Dis. — 2005. — № 40(11). — P. 1586-1590.

Aslam S., Hamill R.J., Musher D.M. Treatment of Clostri­dium difficile-associated disease: old therapies and new strategies // Lancet Infect Dis. — 2005. — № 5(9). — P. 549-557.

Peláez T., Alcalá L., Alonso R., Rodríguez-Créixems M., García-Lechuz J.M. Reassessment of Clostridium difficile susceptibility to metronidazole and vancomycin // Antimicrob Agents Chemother. — 2002. — Vol. 46(6). — P. 1647-1650.

Huebner E.S., Surawicz C.M. Treatment of recurrent Clostridium difficile diarrhea // Gastroenterol. Hepatol. — 2006. — № 2. — P. 203-208.

Григорьева Г.А., Мешалкина Н.Ю. Смекта в лечении заболеваний кишечника // Русский медицинский журнал. — 2005. — Т. 13, № 7. — С. 464.

Мазанкова Л.Н. Вторичная дисахаридазная недостаточность у детей: клиника, диагностика, тактика терапии: Практическое пособие для врачей. — М., 2010. — 13 с.

Martinez F.J., Leffler D.A., Kelly C.P. Clostridium difficile outbreaks: prevention and treatment strategies // Risk Management and Healthcare Policy. — 2012. — № 5. — P. 55-64.

McFarland L.V. Systematic review and meta-analysis of Saccharomyces boulardii in adult patients // World J. Gastroenterol. — 2010 May 14. — Vol. 16(18). — P. 2202-2222.

Johnston B.C., Goldenberg J.Z., Vandvik P.O., Sun X., Guyatt G.H. Probiotics for the prevention of pediatric antibiotic-associated diarrhea // Cochrane Database Syst. Rev. — 2011, Nov 9. — № 11: CD004827. doi: 10.1002/14651858.CD004827.pub3.

Allen S.J., Wareham K., Wang D., Bradley C., Hut­chings H., Harris W., Dhar A., Brown H., Foden A., Gravenor M.B. Lactobacilli and bifidobacteria in the prevention of antibiotic-associated diarrhoea and Clostridium difficile diarrhoea in older inpatients (PLACIDE): a randomised, double-blind, placebo-controlled, multicentre trial // Lancet. — 2013. — Early Online Publication, 8 August.

McFarland L.V. Meta-analysis of probiotics for the prevention of antibiotic associated diarrhea and the treatment of Clostridium difficile ­disease // Am. J. Gastroenterol. — 2006. — Suppl. 101(4). — P. 812-822.

Duman D.G., Kumral Z.N., Ercan F., Deniz M., Can G., Cağlayan Yeğen B. Saccharomyces boulardii ameliorates clarithromycin- and methotrexate-induced intestinal and hepatic injury in rats // Br. J. Nutr. — 2013. — № 2. — P. 1-7.

Czerucka D. et al. Effect of Saccharomyces boulardiion cAMP-Ca2+-dependent Cl- secretion in T84 cells // Dig. Dis. Sci. — 1999. — Vol. 44.— P. 2359-2368.




Copyright (c) 2016 CHILD`S HEALTH

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

 

© Publishing House Zaslavsky, 1997-2018

 

   Seo анализ сайта